Page 4 - Simba Gill News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights Evelo Biosciences, Inc.April 29, 2021 GMT –Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting– –Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors– –Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP181...

Evelo Biosciences, Inc. (EVLO) Q1 2021 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. Evelo Biosciences, Inc. (NASDAQ: EVLO) Q1 2021 Earnings Call Good morning, and welcome to Evelo Biosciences conference call to discuss the first-quarter 2021 financial results and business highlights. [Operator instructions] Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to Jessica Cotrone of Evelo. Please proceed. Jessica Cotrone -- Vice President, Hea...

(0) CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointments of Luca Scavo as Chief Financial Officer (CFO), effective June 1, 2021, and Julie H. McHugh to its Board of Directors, effective immediately. Mr. Scavo brings more than 25 years of international experience in both emerging and developed markets within pioneering biotechnology and diagnostics companies including Genentech, Roche and AstraZeneca, where he led teams across d...

Published: Mar 09, 2021 –Announced new positive data in human experimental model of inflammation of EDP1815– –Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021– –Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021– –Up to 8 clinical data readouts expected over next 18 months– –Management to host conference call at 8:30 a.m. ET– CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology...

(2) -Announced new positive data in human experimental model of inflammation of EDP1815- -Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021- -Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021- -Up to 8 clinical data readouts expected over next 18 months- -Management to host conference call at 8:30 a.m. ET- CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of oral...